Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Pyrrolidine

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    5 result(s) found for: Pyrrolidine. Displaying page 1 of 1.
    EudraCT Number: 2005-003171-21 Sponsor Protocol Number: LEV-2005 Start Date*: 2005-11-02
    Sponsor Name:Danish Pain Research Center
    Full Title: Effect of levetiracetam in spinal cord injury pain: a randomized, double-blind, placebo-controlled crossover study
    Medical condition: Neuropathic pain following spinal cord injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2008-001098-13 Sponsor Protocol Number: NA Start Date*: 2008-04-30
    Sponsor Name:UZ Leuven
    Full Title: Simultaneous administration of lorazepam and levetiracetam in non-convulsive status epilepticus, followed by IV valproate: a prospective, randomized, placebo-controled, double-blind pilot trial.
    Medical condition: Non-convulsive status epilepticus
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006465-38 Sponsor Protocol Number: 21EU-Fpf02 Start Date*: 2022-06-06
    Sponsor Name:IBSA Institut Biochimique S.A.
    Full Title: A Randomized, Double-Blind, Multi-Centre, Placebo-Controlled, Active Comparator Study to Evaluate the Efficacy and Safety of a diclofenac epolamine (DHEP) 2.6% medicated plaster in the treatment of...
    Medical condition: Acute pain in mild/moderate ankle sprains
    Disease: Version SOC Term Classification Code Term Level
    21.1 10022117 - Injury, poisoning and procedural complications 10024453 Ligament sprain PT
    23.1 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    20.0 10022117 - Injury, poisoning and procedural complications 10028288 Muscle, tendon and ligament injuries HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000199-14 Sponsor Protocol Number: N01009 Start Date*: 2004-11-25
    Sponsor Name:UCB Pharma S.A. [...]
    1. UCB Pharma S.A.
    2. UCB Pharma Inc.
    Full Title: A double-blind, randomized, multicenter, placebo-controlled, in-patients maximum 34 day study of levetiracetam oral solution (20-50 mg/kg/day) as adjunctive treatment of refractory partial onset se...
    Medical condition: Epilepsy - Refractory Partial Onset Seizures
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061334 LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed) GB (Completed) BE (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000276-23 Sponsor Protocol Number: 201464 Start Date*: 2016-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
    Medical condition: Systemic amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 16:06:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA